Results published in the New England Journal of Medicine
Press Release
Results published in the New England Journal of Medicine demonstrate that KAF156 shows activity against blood and liver stages of malaria parasites, including artemisinin-resistant parasites
KAF156, currently in phase IIb, is the first compound from a novel class of antimalarials known as imidazolopiperazines
National Malaria Control Program best practice sharing workshop takes place in Senegal, which has made great strides in malaria control
Event brings together delegates from 33 African countries to accelerate malaria elimination efforts
Novartis Malaria Initiative celebrates treatment delivery milestone, with more than 800 million treatments distributed since 2001, including over 300 million dispersible pediatric treatments
Press Release
National Malaria Control Program best practice sharing workshop takes place in Senegal, which has made great strides in malaria control
Event brings together delegates from 33 African countries to accelerate malaria elimination efforts
Novartis Malaria Initiative celebrates treatment delivery milestone, with more than 800 million treatments distributed since 2001, including over 300 million dispersible pediatric treatments
By David Reddy, CEO, Medicines for Malaria Venture and Jürgen Brokatzky-Geiger, Global Head of Corporate Responsibility, Novartis
Blog
No child should ever die from a mosquito bite. Yet, today, in an era of extraordinary medical advancement, a child dies of mosquito-borne malaria every two minutes. Last year, this agonizing blood disease caused by the malaria parasite claimed nearly half a million lives—most of them children.
Novartis will lead the development of antimalarial compound KAF156 with scientific and financial support from Medicines for Malaria Venture in collaboration with the Bill & Melinda Gates Foundation
Summary:
Novartis expands partnership with Medicines for Malaria Venture to develop next-generation antimalarial treatment
Novartis will lead the development of antimalarial compound KAF156 with scientific and financial support from Medicines for Malaria Venture in collaboration with the Bill & Melinda Gates Foundation
KAF156 belongs to a novel class of antimalarials that act against both the blood and liver stages of the parasite’s lifecycle
Antimalarials with new mechanisms of action are urgently needed to tackle emerging parasite resistance to current therapies
Press Release
Novartis expands partnership with Medicines for Malaria Venture to develop next-generation antimalarial treatment
Novartis will lead the development of antimalarial compound KAF156 with scientific and financial support from Medicines for Malaria Venture in collaboration with the Bill & Melinda Gates Foundation
KAF156 belongs to a novel class of antimalarials that act against both the blood and liver stages of the parasite’s lifecycle
Antimalarials with new mechanisms of action are urgently needed to tackle emerging parasite resistance to current therapies
From June 4-7 Novartis scientists participate in the World Congress of Cardiology & Cardiovascular Health (WCC) in Mexico. This Congress brings together thousands of heart health professionals from around the world. One of the key topics is rheumatic heart disease (RHD).
Blog written by Harald Nusser, Global Head Novartis Access
Blog
While the headlines might focus on Ebola or yellow fever, Africa is slowly winning the fight against infectious diseases. They will remain a challenge for decades to come, but the real threat of the future is expected to come from elsewhere: non-communicable diseases (NCDs) like diabetes, cardiovascular disease and cancer.
Nearly one quarter of the adult population in Vietnam has hypertension, but only 11% of these hypertensive patients have it under control
Summary:
Ho Chi Minh City Communities for Healthy Hearts Program is the second innovative healthcare model for hypertension pioneered by the Novartis Foundation
Screening and treatment shifts to the community via social entrepreneurs, while digital health technology empowers patients and health workers
Nearly one quarter of the adult population in Vietnam has hypertension, but only 11% of these hypertensive patients have it under control
Program partners include Ho Chi Minh City’s Provincial Health Department, PATH, the Hanoi School of Public Health and Lotus Impact
Press Release
Ho Chi Minh City Communities for Healthy Hearts Program is the second innovative healthcare model for hypertension pioneered by the Novartis Foundation
Screening and treatment shifts to the community via social entrepreneurs, while digital health technology empowers patients and health workers
Nearly one quarter of the adult population in Vietnam has hypertension, but only 11% of these hypertensive patients have it under control
Program partners include Ho Chi Minh City’s Provincial Health Department, PATH, the Hanoi School of Public Health and Lotus Impact
Malaria is still one of the most deadly diseases in developing countries
Article
Today is World Malaria Day. Malaria is preventable and curable, yet it is still one of the most deadly diseases in developing countries. Despite extraordinary progress in the fight against malaria over the last 15 years, the disease still claims the life of a child every two minutes.
The Novartis Institute for Tropical Diseases convenes parasitology experts in Zambia
Article
On April 4-8 2016, the Novartis Institute for Tropical Diseases (NITD) held a Symposium on Parasitology in Lusaka, Zambia, bringing together international and local experts in the field with the aim of engaging in productive scientific exchange on parasitic diseases - including malaria, sleeping sickness (Human African Trypanosomiasis), Chagas, leishmaniasis, and cryptosporidiosis.
Novartis will provide medicines for high blood pressure and diabetes
Article
Syrian refugees in Lebanon suffering from chronic diseases face difficulties accessing diagnosis, medicines and ongoing care. The International Committee of the Red Cross (ICRC) and Novartis are partnering to improve care and treatment for the most vulnerable population in Lebanon. The objective is to establish a blueprint for improving diagnosis, treatment and follow-up for refugees, as well as members of their Lebanese host families, who suffer from chronic diseases.
